verapamil has been researched along with Bladder Cancer in 36 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated whether verapamil (VR), a known chemosensitizing agent of P-glycoprotein-mediated multidrug resistance, could enhance the preventative effect of doxorubicin (Adriamycin, ADM) on both intravesical recurrence and disease progression after transurethral resection (TUR) of superficial bladder cancer." | 9.08 | Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. The Kyushu University Urological On ( Ariyoshi, A; Hiratsuka, Y; Iguchi, A; Kotoh, S; Kumazawa, J; Naito, S; Omoto, T; Osada, Y; Sagiyama, K, 1998) |
| "A collaborative randomized clinical trial on the intravesical administration of Adriamycin (ADM) with or without verapamil (VR), a calcium-channel blocker, as chemotherapy of superficial bladder cancer (Ta, T1) was carried out at two universities, Okayama and Kagoshima, and their affiliated hospitals." | 9.07 | Intravesical instillation chemotherapy of adriamycin with or without verapamil for the treatment of superficial bladder cancer: the final results of a collaborative randomized trial. ( Kawahara, M; Matsumura, Y; Ohashi, Y; Ohi, Y; Ohmori, H; Shirahama, T; Tsushima, T, 1994) |
| "A prospective randomized trial was conducted to compare the prophylactic effect of intravesical installation of Adriamycin (ADM) plus verapamil (VR) with that of ADM alone for recurrence of superficial bladder cancer." | 9.07 | Prophylactic intravesical chemotherapy with adriamycin plus verapamil for primary superficial bladder cancer: preliminary results. The Kyushu University Urological Oncology Group. ( Ariyoshi, A; Hiratsuka, Y; Iguchi, A; Kotoh, S; Kumazawa, J; Naito, S; Omoto, T; Osada, Y; Sagiyama, K; Ueda, T, 1994) |
| "A case-controlled collaborative study on the intravesical administration of Adriamycin in the presence or absence of verapamil, a calcium-channel blocker, as chemotherapy of superficial bladder cancer was carried out at two universities, Okayama and Kagoshima, and their affiliated hospitals." | 9.07 | Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study. ( Kawahara, M; Matsumura, Y; Ohashi, Y; Ohi, Y; Ohmori, H; Shirahama, T; Tsushima, T, 1992) |
| "The in vitro inhibition of cell growth was examined in a model simulating intravesical chemotherapy using two bladder cancer cell lines (TSGH-8301, HTB9) and three commonly used intravesical cytotoxic agents (doxorubicin, mitomycin C, and thiotepa) in the presence or absence of tamoxifen or verapamil as modulators." | 7.69 | Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy. ( Cheng, AL; Hsieh, CY; Hsieh, TS; Lai, MK; Pu, YS; Su, IJ; Tsai, TC; Tseng, NF, 1996) |
| "Nineteen patients with histologically proven superficial bladder cancer (Ta, T1) were treated with intravesical instillation of 30 mg of adriamycin (ADM) dissolved in 24 ml physiological saline plus 15 mg of verapamil (VR) (6 ml) every day for 10 days." | 7.68 | Intravesical therapy with adriamycin plus verapamil in patients with superficial bladder cancer: a pilot study. ( Ariyoshi, A; Iguchi, A; Kimiya, K; Kumazawa, J; Naito, S; Omoto, T; Osada, Y; Sagiyama, K; Ueda, T, 1992) |
| "We have investigated the effect of verapamil on the cytotoxicity of adriamycin and mitomycin C with human bladder cancer cell lines T-24 and JTC-30." | 7.67 | [Effect of a calcium influx blocker, verapamil, on the sensitivity of human bladder cancer cells to adriamycin and mitomycin C]. ( Kageyama, Y; Kihara, K; Ohta, S; Yoshida, K, 1988) |
| "To examine the effects of verapamil on the intracellular drug pharmacokinetics of epirubicin using alternative dosing schedules." | 5.35 | Time-lapse live cell imaging and flow analysis of multidrug resistance reversal by verapamil in bladder cancer cell lines. ( Birch, BR; Cooper, AJ; Featherstone, JM; Hayes, MC; Lwaleed, BA; Speers, AG, 2009) |
| "Idarubicin is a highly lipophilic anthracycline and appears effective against tumours resistant to conventional anthracyclines." | 5.29 | Confocal microscopy of idarubicin localisation in sensitive and multidrug-resistant bladder cancer cell lines. ( Cooper, A; Duffy, PM; Hayes, MC; Smart, CJ, 1996) |
| "We investigated whether verapamil (VR), a known chemosensitizing agent of P-glycoprotein-mediated multidrug resistance, could enhance the preventative effect of doxorubicin (Adriamycin, ADM) on both intravesical recurrence and disease progression after transurethral resection (TUR) of superficial bladder cancer." | 5.08 | Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. The Kyushu University Urological On ( Ariyoshi, A; Hiratsuka, Y; Iguchi, A; Kotoh, S; Kumazawa, J; Naito, S; Omoto, T; Osada, Y; Sagiyama, K, 1998) |
| "A collaborative randomized clinical trial on the intravesical administration of Adriamycin (ADM) with or without verapamil (VR), a calcium-channel blocker, as chemotherapy of superficial bladder cancer (Ta, T1) was carried out at two universities, Okayama and Kagoshima, and their affiliated hospitals." | 5.07 | Intravesical instillation chemotherapy of adriamycin with or without verapamil for the treatment of superficial bladder cancer: the final results of a collaborative randomized trial. ( Kawahara, M; Matsumura, Y; Ohashi, Y; Ohi, Y; Ohmori, H; Shirahama, T; Tsushima, T, 1994) |
| "A prospective randomized trial was conducted to compare the prophylactic effect of intravesical installation of Adriamycin (ADM) plus verapamil (VR) with that of ADM alone for recurrence of superficial bladder cancer." | 5.07 | Prophylactic intravesical chemotherapy with adriamycin plus verapamil for primary superficial bladder cancer: preliminary results. The Kyushu University Urological Oncology Group. ( Ariyoshi, A; Hiratsuka, Y; Iguchi, A; Kotoh, S; Kumazawa, J; Naito, S; Omoto, T; Osada, Y; Sagiyama, K; Ueda, T, 1994) |
| "A case-controlled collaborative study on the intravesical administration of Adriamycin in the presence or absence of verapamil, a calcium-channel blocker, as chemotherapy of superficial bladder cancer was carried out at two universities, Okayama and Kagoshima, and their affiliated hospitals." | 5.07 | Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study. ( Kawahara, M; Matsumura, Y; Ohashi, Y; Ohi, Y; Ohmori, H; Shirahama, T; Tsushima, T, 1992) |
| "To assess, using epirubicin-sensitive and multidrug resistant (MDR) derivatives of human bladder cancer cell lines in vitro, the probable effect of intravesical pH changes, with and without the MDR antagonist verapamil, on the uptake, intracellular distribution and cytotoxicity of epirubicin during intravesical chemotherapy." | 3.71 | Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer. ( Anderson, WR; Cooper, AJ; Crook, TJ; Duffy, PM; Harris, NM; Hayes, MC; Sharpe, P; Solomon, LZ, 2002) |
| "The in vitro inhibition of cell growth was examined in a model simulating intravesical chemotherapy using two bladder cancer cell lines (TSGH-8301, HTB9) and three commonly used intravesical cytotoxic agents (doxorubicin, mitomycin C, and thiotepa) in the presence or absence of tamoxifen or verapamil as modulators." | 3.69 | Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy. ( Cheng, AL; Hsieh, CY; Hsieh, TS; Lai, MK; Pu, YS; Su, IJ; Tsai, TC; Tseng, NF, 1996) |
| "To develop a method of determining the characteristics of epirubicin resistance and to study the reversal of such resistance in the intravesical treatment of superficial bladder cancer, using sensitive and resistant derivatives of a bladder cancer cell line in vitro." | 3.69 | Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model. ( Cooper, A; Duffy, PM; Hayes, MC; Smart, CJ, 1996) |
| "To evaluate the use of confocal microscopy in the study of resistance to epirubicin and to determine the effect of temperature, viability and a resistance-reversing agent on the intracellular distribution of this drug in sensitive and resistant derivatives of a superficial bladder cancer cell line." | 3.69 | Determination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging study. ( Cooper, A; Duffy, PM; Gatrell, SK; Hayes, MC; Smart, CJ, 1996) |
| "Nineteen patients with histologically proven superficial bladder cancer (Ta, T1) were treated with intravesical instillation of 30 mg of adriamycin (ADM) dissolved in 24 ml physiological saline plus 15 mg of verapamil (VR) (6 ml) every day for 10 days." | 3.68 | Intravesical therapy with adriamycin plus verapamil in patients with superficial bladder cancer: a pilot study. ( Ariyoshi, A; Iguchi, A; Kimiya, K; Kumazawa, J; Naito, S; Omoto, T; Osada, Y; Sagiyama, K; Ueda, T, 1992) |
| "The effect of calcium antagonist verapamil on the uptake and efflux of Etoposide (VP16), a semi-synthetic derivative of podophylotoxin and a broad spectrum antineoplastic agent, has been investigated and compared in sensitive (UM-UC-2) and resistant (UM-UC-9) human bladder cancer cells, and L1210 leukemia cells, by using both radioisotope (3[H]-VP16) liquid scintillation and high performance liquid chromatography assay with electrochemical detection." | 3.68 | Effect of verapamil on the uptake and efflux of etoposide (VP16) in both sensitive and resistant cancer cells. ( Feng, MR; Grossman, HB; Liebert, M; Mancini, WR; Wagner, JG; Wedemeyer, G; Williams, M, 1991) |
| "A chemosensitivity test was carried out on superficial bladder cancers using the trypan blue dye exclusion assay for the purpose of screening chemosensitive drugs for intravesical chemotherapy." | 3.68 | [Chemosensitivity test on superficial urinary bladder cancer using the dye exclusion assay--model of intravesical chemotherapy]. ( Irisawa, C; Koseki, K; Shiraiwa, Y, 1991) |
| "We have investigated the effect of verapamil on the cytotoxicity of adriamycin and mitomycin C with human bladder cancer cell lines T-24 and JTC-30." | 3.67 | [Effect of a calcium influx blocker, verapamil, on the sensitivity of human bladder cancer cells to adriamycin and mitomycin C]. ( Kageyama, Y; Kihara, K; Ohta, S; Yoshida, K, 1988) |
| "To examine the effects of verapamil on the intracellular drug pharmacokinetics of epirubicin using alternative dosing schedules." | 1.35 | Time-lapse live cell imaging and flow analysis of multidrug resistance reversal by verapamil in bladder cancer cell lines. ( Birch, BR; Cooper, AJ; Featherstone, JM; Hayes, MC; Lwaleed, BA; Speers, AG, 2009) |
| "P-glycoprotein can be expressed on bladder cancer cells without prior chemotherapy." | 1.29 | P-glycoprotein expression in bladder cancer. ( Flint, A; Grossman, HB; Liebert, M; Noto, L; Park, J; Shinohara, N, 1994) |
| "A human bladder cancer cell line resistant to adriamycin (ADM), T24/ADM9 has been established in vitro by exposing T24 parent cells to progressively higher concentrations of the drug over a period of 12 months." | 1.29 | Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line. ( Hasegawa, S; Koga, H; Kotoh, S; Kumazawa, J; Kuwano, M; Naito, S; Yokomizo, A, 1995) |
| "Idarubicin is a highly lipophilic anthracycline and appears effective against tumours resistant to conventional anthracyclines." | 1.29 | Confocal microscopy of idarubicin localisation in sensitive and multidrug-resistant bladder cancer cell lines. ( Cooper, A; Duffy, PM; Hayes, MC; Smart, CJ, 1996) |
| "A human bladder cancer cell line resistant to doxorubicin, KK47/ADM has been established in vitro by exposing KK47 parent cells to progressively higher concentrations of the drug over a period of 16 months." | 1.28 | Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM. ( Kimiya, K; Kotoh, S; Kumazawa, J; Naito, S; Sakamoto, N; Soejima, T; Tsuruo, T, 1992) |
| "Verapamil was found in high concentrations in the mucosa, less in the adventitia, and was absent in venous blood." | 1.28 | The effect of verapamil on a multi-drug resistant bladder carcinoma cell line and its potential as an intravesical chemotherapeutic agent. ( Lin, CW; Long, JP; Prout, GR; Wong, YK, 1990) |
| " The dosage of Verapamil necessary for maintaining an effective concentration for enhancement of the anti-tumor drug was determined and the influences of bladder instillation of Verapamil on the cardiovascular system and on the bladder were studied." | 1.27 | [Bladder instillation of verapamil as a means of enhancing the efficacy of chemotherapy in superficial bladder carcinoma: influence of bladder instillation of verapamil on the cardiovascular system]. ( Horiuchi, S; Kaneoya, F; Nakame, Y; Negishi, T; Saitoh, H; Takahashi, T; Yoshida, K, 1987) |
| "Verapamil was found to enhance the activity of both ADR and AD-32 against a HBTCL (T24), found to be resistant to both agents." | 1.27 | Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines. ( Herrod, HG; Hunter, RF; Israel, M; Niell, HB, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (19.44) | 18.7374 |
| 1990's | 24 (66.67) | 18.2507 |
| 2000's | 5 (13.89) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Featherstone, JM | 1 |
| Lwaleed, BA | 1 |
| Speers, AG | 1 |
| Hayes, MC | 5 |
| Birch, BR | 1 |
| Cooper, AJ | 2 |
| Harris, NM | 1 |
| Duffy, PM | 4 |
| Crook, TJ | 1 |
| Anderson, WR | 1 |
| Sharpe, P | 1 |
| Solomon, LZ | 1 |
| Burgués, JP | 1 |
| Gómez, L | 1 |
| Pontones, JL | 1 |
| Vera, CD | 1 |
| Jiménez-Cruz, JF | 1 |
| Ozonas, M | 1 |
| Simpson, WG | 2 |
| Tseng, MT | 3 |
| Anderson, KC | 1 |
| Harty, JI | 3 |
| Seemann, O | 1 |
| Muscheck, M | 1 |
| Siegsmund, M | 1 |
| Pilch, H | 1 |
| Nebe, CT | 1 |
| Rassweiler, J | 1 |
| Alken, P | 1 |
| Park, J | 1 |
| Shinohara, N | 2 |
| Liebert, M | 4 |
| Noto, L | 1 |
| Flint, A | 1 |
| Grossman, HB | 4 |
| Liu, NB | 1 |
| Tsushima, T | 2 |
| Ohmori, H | 3 |
| Ohi, Y | 2 |
| Shirahama, T | 2 |
| Kawahara, M | 2 |
| Matsumura, Y | 3 |
| Ohashi, Y | 2 |
| Naito, S | 5 |
| Ueda, T | 2 |
| Kotoh, S | 4 |
| Iguchi, A | 3 |
| Sagiyama, K | 3 |
| Hiratsuka, Y | 2 |
| Osada, Y | 3 |
| Ariyoshi, A | 3 |
| Omoto, T | 3 |
| Kumazawa, J | 5 |
| Iinuma, S | 1 |
| Farshi, SS | 1 |
| Ortel, B | 1 |
| Hasan, T | 1 |
| Sugimoto, K | 1 |
| Wedemeyer, G | 3 |
| Chang, JH | 1 |
| Etiévant, C | 1 |
| Pauwels, O | 1 |
| Kiss, R | 1 |
| Hasegawa, S | 1 |
| Yokomizo, A | 1 |
| Koga, H | 1 |
| Kuwano, M | 1 |
| Pu, YS | 1 |
| Hsieh, TS | 1 |
| Cheng, AL | 1 |
| Tseng, NF | 1 |
| Su, IJ | 1 |
| Hsieh, CY | 1 |
| Lai, MK | 1 |
| Tsai, TC | 1 |
| Cooper, A | 3 |
| Smart, CJ | 3 |
| Gatrell, SK | 1 |
| Schuldes, H | 1 |
| Dolderer, JH | 1 |
| Schoch, C | 1 |
| Bickeböller, R | 1 |
| Woodcock, BG | 1 |
| Hashimoto, H | 1 |
| Tokumitsu, M | 1 |
| Saga, Y | 1 |
| Okuyama, M | 1 |
| Yachiku, S | 1 |
| Kimiya, K | 2 |
| Soejima, T | 1 |
| Sakamoto, N | 1 |
| Tsuruo, T | 1 |
| Feng, MR | 1 |
| Mancini, WR | 1 |
| Williams, M | 1 |
| Wagner, JG | 2 |
| Usansky, JI | 1 |
| Koseki, K | 1 |
| Irisawa, C | 1 |
| Shiraiwa, Y | 1 |
| Lukkarinen, O | 1 |
| Paul, C | 1 |
| Hellström, P | 1 |
| Kontturi, M | 1 |
| Nurmi, M | 1 |
| Puntala, P | 1 |
| Ottelin, J | 1 |
| Tammela, T | 1 |
| Tidefeldt, U | 1 |
| Long, JP | 1 |
| Prout, GR | 1 |
| Wong, YK | 1 |
| Lin, CW | 1 |
| Ueda, K | 1 |
| Ballou, RJ | 1 |
| Kageyama, Y | 1 |
| Kihara, K | 1 |
| Ohta, S | 1 |
| Yoshida, K | 2 |
| Yoshimoto, J | 1 |
| Saegusa, M | 1 |
| Ochi, J | 1 |
| Hara, M | 1 |
| Akagi, T | 1 |
| Obama, T | 1 |
| Tanahashi, T | 1 |
| Takahashi, T | 1 |
| Nakame, Y | 1 |
| Saitoh, H | 1 |
| Horiuchi, S | 1 |
| Kaneoya, F | 1 |
| Negishi, T | 1 |
| Niell, HB | 1 |
| Hunter, RF | 1 |
| Herrod, HG | 1 |
| Israel, M | 1 |
| Simpson, W | 1 |
5 trials available for verapamil and Bladder Cancer
| Article | Year |
|---|---|
Intravesical instillation chemotherapy of adriamycin with or without verapamil for the treatment of superficial bladder cancer: the final results of a collaborative randomized trial.
Topics: Administration, Intravesical; Adult; Aged; Cystoscopy; Doxorubicin; Drug Synergism; Drug Therapy, Co | 1994 |
Prophylactic intravesical chemotherapy with adriamycin plus verapamil for primary superficial bladder cancer: preliminary results. The Kyushu University Urological Oncology Group.
Topics: Administration, Intravesical; Aged; Chemotherapy, Adjuvant; Doxorubicin; Drug Therapy, Combination; | 1994 |
Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. The Kyushu University Urological On
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherap | 1998 |
Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystoscopy; Doxo | 1992 |
Intravesical epirubicin with and without verapamil for the prophylaxis of superficial bladder tumours.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Drug Synerg | 1991 |
31 other studies available for verapamil and Bladder Cancer
| Article | Year |
|---|---|
Time-lapse live cell imaging and flow analysis of multidrug resistance reversal by verapamil in bladder cancer cell lines.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Nucleus; Cytoplasm | 2009 |
Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Drug Resist | 2002 |
A chemosensitivity test for superficial bladder cancer based on three-dimensional culture of tumour spheroids.
Topics: Antineoplastic Agents; Ciprofloxacin; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, | 2007 |
Verapamil enhancement of chemotherapeutic efficacy in human bladder cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Division; Cell Li | 1984 |
Establishment and characterization of a multidrug-resistant human bladder carcinoma cell line RT112/D21.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Cell Divi | 1995 |
P-glycoprotein expression in bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Bindi | 1994 |
[Intravesical instillation of combined adriamycin and verapamil in preventing recurrence of superficial bladder tumor].
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Bindi | 1993 |
A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Division; | 1994 |
[Effect of verapamil on adriamycin resistant bladder tumor cells].
Topics: Animals; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Male; Rats; Rats, Wistar; Tu | 1994 |
Evaluation of multiple drug resistance in human bladder cancer cell lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; C | 1993 |
Digital cell image analysis of verapamil-induced effects in chemosensitive and chemoresistant neoplastic cell lines.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Aziridines; Cell Division; Diamines; Dose-Resp | 1993 |
Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette | 1995 |
Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy | 1996 |
Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Dose-Response Relationship, Drug; Drug Re | 1996 |
Determination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging study.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Drug Resistance, Multiple; Drug Resistanc | 1996 |
Confocal microscopy of idarubicin localisation in sensitive and multidrug-resistant bladder cancer cell lines.
Topics: Antibiotics, Antineoplastic; Cell Nucleus; Drug Resistance, Multiple; Humans; Idarubicin; Microscopy | 1996 |
Cytostatic sensitivity and MDR in bladder carcinoma cells: implications for tumor therapy.
Topics: Antineoplastic Agents; Calcium Channel Blockers; Carcinoma, Transitional Cell; Cisplatin; Doxorubici | 2000 |
Immunohistochemical expression of P-glycoprotein in the rat urinary bladder and the effect of verapamil on intravesical chemotherapy.
Topics: Administration, Intravesical; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calc | 2001 |
Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Transitional Cell; Doxorubicin; | 1992 |
Intravesical therapy with adriamycin plus verapamil in patients with superficial bladder cancer: a pilot study.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Doxorubicin; Drug Therapy, Combina | 1992 |
Effect of verapamil on the uptake and efflux of etoposide (VP16) in both sensitive and resistant cancer cells.
Topics: Animals; Carcinoma, Transitional Cell; Culture Media; Drug Resistance; Etoposide; Glucose; Humans; K | 1991 |
The uptake and efflux of doxorubicin by a sensitive human bladder cancer cell line and its doxorubicin-resistant subline.
Topics: Chromatography, High Pressure Liquid; Doxorubicin; Drug Resistance; Humans; Tumor Cells, Cultured; U | 1991 |
[Chemosensitivity test on superficial urinary bladder cancer using the dye exclusion assay--model of intravesical chemotherapy].
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubi | 1991 |
The effect of verapamil on a multi-drug resistant bladder carcinoma cell line and its potential as an intravesical chemotherapeutic agent.
Topics: Animals; Carcinoma, Transitional Cell; Cell Line; Cell Survival; Dose-Response Relationship, Drug; D | 1990 |
[The treatment of superficial bladder carcinoma with intravesical HPC-adriamycin and verapamil].
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cellulose | 1990 |
Verapamil enhanced in vitro chemosensitivity of a murine bladder carcinoma, FCB.
Topics: Animals; Carcinoma, Transitional Cell; Cell Division; Cells, Cultured; Dose-Response Relationship, D | 1986 |
[Effect of a calcium influx blocker, verapamil, on the sensitivity of human bladder cancer cells to adriamycin and mitomycin C].
Topics: Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Humans; In Vitro Techniques; Mitomyci | 1988 |
[Intravesical chemotherapy of adriamycin and verapamil in patients with recurrent superficial bladder cancer: preliminary report].
Topics: Administration, Intravesical; Adult; Aged; Doxorubicin; Drug Therapy, Combination; Humans; Male; Mid | 1987 |
[Bladder instillation of verapamil as a means of enhancing the efficacy of chemotherapy in superficial bladder carcinoma: influence of bladder instillation of verapamil on the cardiovascular system].
Topics: Administration, Intravesical; Aged; Antineoplastic Agents; Blood Pressure; Drug Therapy, Combination | 1987 |
Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines.
Topics: Biological Transport; Cell Line; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance; Drug Sy | 1987 |
Ultrastructural evaluation of murine bladder epithelium exposed to verapamil.
Topics: Animals; Epithelium; Female; Mice; Mice, Inbred C57BL; Microscopy, Electron; Urinary Bladder; Urinar | 1985 |